ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company’s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Wednesday, June 1, 2011, for shareholders of record on April 11, 2011. The Annual Meeting will be held at the company’s headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Annual Meeting, as well as its annual report, in late-April.
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance™ (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305) for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.
BESIVANCE™ is a trademark of Bausch & Lomb Incorporated.
Louis Drapeau, 510-747-1220
Chief Financial Officer
Michelle Corral, 415-794-8662
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Optical Pharmaceutical